Beihai Kangcheng-B: Injection of Virellanase for use has obtained marketing approval in China.

Beihai Kangcheng-B announced that the injectable enzyme vilaenase has been granted marketing approval by the China National Medical Products Administration on May 15, 2025, for the treatment of Type I and Type III Gaucher's disease. The company holds global exclusive rights to develop and commercialize the product. Gaucher's disease is one of the most common lysosomal storage diseases, caused by mutations in the glucocerebrosidase gene located on the long arm of chromosome 1q22, an autosomal recessive genetic disease. The disease affects males and females equally. Clinically, Gaucher's disease includes Type 0, Type I, Type II, and Type III, with Type I and Type III patients often surviving into adulthood. Gorinene is the first domestically developed long-term enzyme replacement therapy for Type I and Type III Gaucher's disease patients aged 12 and above. As an innovative drug, it can fully substitute for similar imported products, greatly improving the accessibility of medication for domestic patients.